SCHEMBL23419277

SCHEMBL23419277

COc1ccc(-c2nccn3c(=O)n(Cc4nc5c(Cl)c(Cl)ccc5[nH]4)cc23)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MARS2 Q96GW9 3/20 0.42
▸ KDM4E B2RXH2 1/20 0.33
▸ GRIN1 Q05586 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33
▸ PDE2A O00408 5/20 0.32
▸ CRHR1 P34998 3/20 0.32
▸ CDC7 O00311 2/20 0.31
▸ DBF4 Q9UBU7 2/20 0.31
▸ CCNT1 O60563 1/20 0.31
▸ CSNK2A2 P19784 1/20 0.31
▸ CCNE1 P24864 1/20 0.31
▸ CDK2 P24941 1/20 0.31
▸ CSNK1A1 P48729 1/20 0.31
▸ CSNK1D P48730 1/20 0.31
▸ CDK9 P50750 1/20 0.31
▸ CSNK2B P67870 1/20 0.31
▸ CSNK2A1 P68400 1/20 0.31
▸ HCRTR1 O43613 1/20 0.30
▸ HCRTR2 O43614 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20596098 0.87 MARS2 (0.37) MARS2KDM4EGRIN1GRIN2BPDE2A
SCHEMBL20596009 0.87 MARS2 (0.57) MARS2KDM4EGRIN1GRIN2BCRHR1
SCHEMBL30145067 0.87 MARS2 (0.57) MARS2KDM4EGRIN1GRIN2BCRHR1
SCHEMBL30145265 0.77 MARS2 (0.49) MARS2PDE2ACRHR1
SCHEMBL20595930 0.77 MARS2 (0.49) MARS2PDE2ACRHR1
SCHEMBL20595872 0.72 FPR2 (0.42) KDM4EGRIN1GRIN2BCRHR1CDC7
SCHEMBL23419588 0.69 MARS2 (0.61) MARS2PDE2AHCRTR1HCRTR2
SCHEMBL20595855 0.64 MARS2 (0.51) MARS2
SCHEMBL30145258 0.64 MARS2 (0.51) MARS2
SCHEMBL20595847 0.63 MARS2 (0.61) MARS2PDE2AHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 MARS2 12/4885KDM4E 1618/4885GRIN1 1189/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR MARS2 5/4885KDM4E 1423/4885GRIN1 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback